Headlines

Ruxolitinib May Improve Symptom Control in Patients With CLL

Ruxolitinib May Improve Symptom Control in Patients With CLL

In this study, researchers evaluated whether ruxolitinib, a JAK2 inhibitor that reduces symptoms in patients with myelofibrosis, would improve disease-related symptoms in patients with CLL.

Adding Bortezomib to Rd Improves PFS, OS in Newly Diagnosed Myeloma

Adding Bortezomib to Rd Improves PFS, OS in Newly Diagnosed Myeloma

Researchers investigated whether VRd, which has demonstrated significant efficacy in newly diagnosed multiple myeloma, would improve outcomes in patients with previously untreated myeloma who are not planned for immediate ASCT.

3-drug Regimen With Ricolinostat Active, Safe in Multiple Myeloma

3-drug Regimen With Ricolinostat Active, Safe in Multiple Myeloma

Researchers report on an evaluation of the safety and preliminary efficacy of the HDAC6-selective inhibitor ricolinostat in combination with standard proteasome inhibitor therapy for relapsed or refractory multiple myeloma.

Lung Cancer Navigator App Aims to Help Patients Understand Disease

Lung Cancer Navigator App Aims to Help Patients Understand Disease

Lung Cancer Navigator, a mobile, customizable app from LUNGEVITY, helps patients with lung cancer better understand their disease, manage medications, track symptoms, and access support.

Hypnosis and Its Use in Cancer Treatment

Hypnosis and Its Use in Cancer Treatment

A cursory look at hypnosis and where it may be used to offer an alternative and side-effect-free management of several aspects of care that can be beneficial to patients with cancer.

Menopause-specific QoL Changes Associated With Chemoprevention Nonadherence

Menopause-specific QoL Changes Associated With Chemoprevention Nonadherence

A cohort of participants in the MAP.3 trial completed the MENQOL questionnaire, and the findings shed light on the influence of changes in menopause-specific quality of life on aromatase inhibitor adherence in women at high risk for breast cancer.

Diarrhea Common But Manageable With Pertuzumab-containing Regimens

Diarrhea Common But Manageable With Pertuzumab-containing Regimens

Because treatment with pertuzumab could include adverse events similar to those observed with EGFR antagonists, such as diarrhea, researchers evaluated participants from 3 trials to determine the incidence and severity of diarrhea observed with pertuzumab.

Longer Dosing Interval of Zoledronic Acid May Be Acceptable for Bone Metastases

Longer Dosing Interval of Zoledronic Acid May Be Acceptable for Bone Metastases

Results from a phase 3 trial comparing a 12-week dosing interval with the standard 4-week dosing interval of zoledronic acid to reduce the incidence of skeletal-related events and pain in patients with bone metastases.

Serum IL-12 May Predict for Chemotherapy-Related Fatigue in Early-Stage Breast Cancer

Serum IL-12 May Predict for Chemotherapy-Related Fatigue in Early-Stage Breast Cancer

In this study, researchers sought to identify physical, neurocognitive, and serologic markers that may correlate with self-reported fatigue before and after (neo)adjuvant chemotherapy for patients with early-stage breast cancer.

Considerable Shifts in NSCLC Treatment With Modest Gains in Survival

Considerable Shifts in NSCLC Treatment With Modest Gains in Survival

Investigators report on trends in treatment of advanced-stage NSCLC from 2000 to 2011, including impact on survival and total Medicare spending.

Conference Coverage

Elotuzumab Regimen Active in High-risk Smoldering Multiple Myeloma

A study presented at 2016 ASH annual meeting demonstrated that the combination of elotuzumab, lenalidomide, and dexamethasone has potential in patients with high-risk smoldering multiple myeloma, a population that would otherwise not receive treatment.

Second Round of Treatment Does Not Improve PFS in Multiple Myeloma

A study presented at the 2016 Annual Meeting of ASH assessed the impact of additional interventions on progression-free survival in patients with multiple myeloma.

Osimertinib New Standard of Care for T790M+ Advanced NSCLC

A study presented at the World Conference on Lung Cancer compared progression-free survival after treatment with osimertinib with that of platinum therapy plus pemetrexed in a select group of patients with T790M-positive advanced NSCLC.

Scalp-cooling Device To Reduce Chemotherapy-related Alopecia

A new system appears efficacious in preventing chemotherapy-related alopecia in women with breast cancer, according to a study presented at SABCS 2016.

Menopause-related Nausea/Vomiting and Headaches Effects Tamoxifen Adherence

Women who experienced menopause-related side effects were significantly less likely to adhere to their assigned tamoxifen therapy.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs